Clay B. Siegall

Co-Founder at Seattle Genetics, Inc.

Clay B. Siegall

Clay B. Siegall

Co-Founder at Seattle Genetics, Inc.

Overview
Career Highlights

Life Science Washington
Seattle Genetics, Inc.

RelSci Relationships

1005

Number of Boards

9

Birthday

1961

Age

58

Contact Data
Trying to get in touch with Clay B. Siegall? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Clay B. Siegall likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer at Syros Pharmaceuticals, Inc.

Relationship likelihood: Strong

Former President & Chief Executive Officer at InterMune, Inc.

Relationship likelihood: Strong

Founder, President & Chief Executive Officer at Ultragenyx Pharmaceutical, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Atreca, Inc.

Relationship likelihood: Strong

Consultant at Aerie Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Life Sciences Discovery Fund

Relationship likelihood: Strong

Chief Financial & Accounting Officer at Seattle Genetics, Inc.

Relationship likelihood: Strong

Co-Founder at Ascenta Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Baker Bros. Advisors LP

Relationship likelihood: Strong

Founder at Samsara Biocapital LLC

Relationship likelihood: Strong

Paths to Clay B. Siegall
Potential Connections via
Relationship Science
You
Clay B. Siegall
Co-Founder at Seattle Genetics, Inc.
Education
B.S. in Zoology

The University of Maryland, College Park is a public research university, the flagship campus of the University System of Maryland, and the original 1862 land-grant institution in the State. The University of Maryland is committed to achieving excellence as the State’s primary center of research and graduate education and the institution of choice for undergraduate students of exceptional ability and promise. The University creates and applies knowledge for the benefit of the economy and culture of the State, the region, the nation, and beyond. As the flagship of the University System of Maryland, the University shares its research, educational, cultural, and technological strengths with businesses, government, and other educational institutions. The University counts among its greatest strengths -- and a major component of its excellence -- the diversity of its faculty, students, and staff. The University of Maryland, College Park is committed to equal educational opportunity and strives to hire a diverse faculty and staff of exceptional achievement through affirmative actions, to celebrate diversity in all of its programs and activities, and to recruit and retain qualified graduate and undergraduate minority students.

PhD in Genetics

The George Washington University actively engages Washington, D.C., and the world. Their location in the heart of Washington places them at the core of U.S. government, policy and law. They sit where the worlds of science, technology, media and the arts converge. Their students and faculty have the unparalleled opportunity to study and work alongside leaders and practitioners in every discipline, to take part in the interchanges that shape our community and the world. The George Washington University was created in 1821 through an Act of Congress, fulfilling George Washington’s vision of an institution in the nation’s capital dedicated to educating and preparing future leaders. Today, GW is the largest institution of higher education in the District of Columbia. They have more than 20,000 students—from all 50 states, the District and more than 130 countries—studying a rich range of disciplines: from forensic science and creative writing to international affairs and computer engineering, as well as medicine, public health, the law and public policy. GW comprises three campuses—Foggy Bottom and Mount Vernon in Washington, D.C., and the GW Virginia Science and Technology Campus in Ashburn, Va.—as well as several graduate education centers in the metropolitan area and Hampton Roads, Va.

Career History
Co-Founder
1997 - Current

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Various Designation
1991 - 1997

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$10K +
2014

Fred Hutchinson Cancer Research Center provides research services for the prevention, early detection, and treatment of cancer and other diseases in the United States and other countries. The research center is engaged in researches to prevent, detect, and treat cancer, HIV/AIDS, and other life-threatening diseases. Its activities in the areas of diseases and research cover fundamental research, prevention, early detection, treatment and cures, and survivorships. Researchers of Fred Hutchinson Cancer Research Center pioneered bone-marrow transplantation for leukemia and other blood diseases. This research has cured thousands of patients worldwide and has boosted survival rates for certain forms of leukemia from zero to 85 percent.

$10K - $25K
2013

Fred Hutchinson Cancer Research Center provides research services for the prevention, early detection, and treatment of cancer and other diseases in the United States and other countries. The research center is engaged in researches to prevent, detect, and treat cancer, HIV/AIDS, and other life-threatening diseases. Its activities in the areas of diseases and research cover fundamental research, prevention, early detection, treatment and cures, and survivorships. Researchers of Fred Hutchinson Cancer Research Center pioneered bone-marrow transplantation for leukemia and other blood diseases. This research has cured thousands of patients worldwide and has boosted survival rates for certain forms of leukemia from zero to 85 percent.

Political Donations
$1,000
2012

Representative from Washington's 1st Congressional District

$1,000
2012

Senator from Washington

$1,000
2012

Former President of United States

Investments
Details Hidden

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.

Details Hidden

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Public Holdings
Restricted data only for RelSci Professional users.
Events
Speaker
New York City, NY
2013 UBS Global Healthcare Conference

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Clay B. Siegall. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Clay B. Siegall's profile does not indicate a business or promotional relationship of any kind between RelSci and Clay B. Siegall.